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Objectives. This study sought to ascertain whether early and 
12-month clinical outcomes after percutaneous coronary revascu- 
larization have improved between 1986-1987 and 1991. 
Background. Since the mid-1980s, when the results of percuta- 
neous revascularization were considered to be somewhat static, 
justifying large-scale clinical trials of percutaneous transluminal 
coronary angioplasty versus other modes of therapy, balloon 
technology has improved, and several new percutaneous revascu- 
larization techniques have become available. The clinical results 
of the current integrated approach to revascularization compared 
with those for coronary angioplasty alone in the late 1980s are not 
known. 
Methods. In this prospective case-control study, 200 consecu- 
tively treated patients with multivessel disease in 1991 were 
studied prospectively and compared with 400 consecutive patients 
from the same centers during 1986-1987. Patients from 1991 were 
matched with earlier patients on the basis of four previously 
described prognostic determinants (left ventricular ejection frac- 
tion, presence of unstable angina, diabetes and target lesion 
morphology score) and the treating institution and were assessed 
for treatment outcome (completeness of revascularization, proce- 
dural success and event-free survival [freedom from death, myo- 
cardial infarction and further revascularization]). 
Results. The 1991 cohort of patients was older (mean [-+SD] 
age 62 -+ 11 vs. 58 -+ 11 years, p < 0.001) and tended to have 
slightly worse left ventricular function (ejection fraction 56 + 10% 
vs. 58 -+ 11%, p = 0.009) than the 1986-1987 cohort. Overall 
lesion morphology risk scores were similar. New devices (other 
than coronary angioplasty) were used in 26% of patients. The 1991 
patient cohort had more frequent total revascularization (35% vs. 
21%, p = 0.003), fewer emergency bypass operations (1.0% vs. 
5.5%, p = 0.006) and an improved overall procedural success rate 
(90% vs. 84%, p = 0.04). In addition, at 12 months the event-free 
survival rate was superior in the 1991 cohort (73.3% vs. 63.6%, 
p = 0.02), although there was no difference in infarct-free survival 
rate (94.6% vs. 93.2%, p = NS). 
Conclusions. Improved results with percutaneous revascular- 
ization in 1991 have important implications for patient care and 
interpretation of ongoing randomized trials enrolling patients in 
the late 1980s and intending to compare standard coronary 
angioplasty with other forms of therapy. 
(JAm Coil Cardiol 1995;25:1137-42) 
Recognition of the limitations of percutaneous transluminal 
coronary angioplasty--abrupt vessel closure in 4% to 10% of 
patients (1,2) and restenosis in 30% to 49% of lesions (3-7)--  
led in the mid-1980s to the development of several alternative 
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or adjunctive means of percutaneous coronary revasculariza- 
tion. At the same time, the technique of coronary angioplasty 
was considered stable enough to warrant commitment o 
large-scale randomized trials designed to assess its appropriate 
role relative to other established therapies for coronary artery 
disease. Now, with many such trials reporting preliminary 
results (4,8-10), several new therapies (directional and rota- 
tional atherectomy, excimer laser, metallic stents) have be- 
come available for clinical application. To date, no study has 
examined whether these newer therapies, applied in an inte- 
grated manner with coronary angioplasty, or further refine- 
ments in the technique of coronary angioplasty, may have 
altered the outcome of percutaneous intervention relative to 
previous tandards. 
The Multivessel Angioplasty Prognosis Study (MAPS) 
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group was formed to investigate predictors of outcome with 
coronary angioplasty as it was practiced in 1986-1987 in 
patients with multivessel disease. A comprehensive data base 
was established (11,12). The purpose of this prospective inves- 
tigation was to determine whether, with the availability in 1991 
of multiple new technologies at the five high volume interven- 
tional centers contributing to the 1986-1987 registry, either 
the type of patients or lesions being treated or the outcome of 
that treatment had changed. 
Methods  
Study overview. The present study was formulated in two 
parts: 1) an unmatched treatment analysis in which types of 
patients and lesions treated in 1986-1987 and 1991 were to be 
compared; and 2) a matched case-control utcome analysis in 
which clinical outcomes of patients treated in 1986-1987 and 
1991 were compared after matching for several key variables. 
Patients and treatment. The baseline 1986-1987 patients 
have been described elsewhere (11). To that group an addi- 
tional 50 patients meeting the same entrance criteria, consec- 
utively treated beginning on January 1, 1986 at a fifth institu- 
tion, were enrolled retrospectively in anticipation of the 
center's participation i the study reported herein. 
The current 1991 phase of the MAPS study prospectively 
enrolled 200 consecutively treated patients meeting identical 
entrance criteria from the same institutions, with treatment 
beginning on January 1, 1991 (except at one center in which 
enrollment began on October 1, 1991 because of first availabil- 
ity of stents at that time). No patients receiving periprocedural 
anticoagulant agents other than aspirin, dipyridamole, heparin 
or dextran were included. 
The choice of which device to use in any clinical situation 
was left to the individual operators, but experience with the 
devices had accrued such that the Rotablator was the most 
commonly used device for heavily calcified or ostial lesions, or 
both, and directional atherectomy was used frequently as the 
preferred evice for proximal and eccentric lesions in large 
(->3.0 ram) arteries. The techniques of device usage has been 
described elsewhere (13-17). 
Clinical variables and follow-up. The following variables 
were assessed and recorded on dedicated case report forms by a 
physician or trained research nurse: age, Canadian Cardiovascu- 
lar Society angina class, current smoking, diabetes mellitus, 
gender, previous myocardial infarction, previous restenosis and 
unstable angina. All definitions used have been previously pub- 
lished (11). Methods of follow-up have also been described (18). 
Angiographie analysis. The cineangiograms were assessed 
at the Angiographic Core Laboratory using the same technique 
and supervisor as in the 1986-1987 study. Coding was per- 
formed by an experienced angiographer who had no knowl- 
edge at the time of the analysis of both the revascularization 
technique used (section taped over) and the clinical outcome. 
Variables coded included bifurcation stenosis, calcification, 
chronic total occlusion, eccentric stenosis, high grade stenosis, 
irregular contour, lesion length, modified American College of 
Cardiology/American Heart Association (ACC/AHA) score, 
ostial stenosis, proximal stenosis location (19), stenosis angle 
->45 °, thrombus and tortuosity. Methodology for dimensional 
measurements (calipers) and definitions have been published 
elsewhere (11). 
Definitions. Complications = myocardial infarction, emer- 
gency bypass surgery or death during index hospital stay. 
Event-free survival = freedom from death, myocardial infarc- 
tion, bypass urgery or further percutaneous revascularization 
(other than intentionally staged procedures). Myocardial infarc- 
tion = development of new pathologic Q waves or elevation of 
creatine kinase (CK) to three or more times the upper limit of 
normal for the laboratory, with CK MB fraction ->4%. Suc- 
cessful treatment = reduction of diameter stenosis to <50% 
without complications. Significant lesion = any stenosis ->50% 
in diameter in a coronary artery measuring >1.5 ram. Target 
lesion = a primary target stenosis (11) was identified prospec- 
tively on the basis of the severity and morphologic character- 
istics of the stenoses, their jeopardized territories, the pre- 
sumed viability of the myocardium observed and available 
clinical data. 
Matching. A matched case-control analysis is regarded as 
the most efficient and reliable method to study relatively rare 
events (20,21). Therefore, on the basis of previous work 
determining that left ventricular ejection fraction, presence of 
unstable angina, diabetes and target vessel morphology are key 
determinants of clinical outcome in patients with multivessel 
disease undergoing coronary angioplasty (8,9), a 2 × 2 x 2 x 
4 matching matrix was generated, separating left ventricular 
ejection fraction into two groups (-<40% and >40%) and 
morphology into four groups based on the modified ACC/ 
AHA criteria (11). For each patient in the 1991 cohort, 
matching patients in the 1986-1987 cohort were identified, and 
then a random number generator was used to select one of the 
patients to construct he 1986-1987 matched cohort. In a 
similar manner, but with 1:2 matching, lesions treated with new 
devices in the 1991 cohort were matched on the basis of lesion 
morphology (e.g., calcification [yes, no], length [-<9, 10 to 19, 
->20 mm] and location [vessel, proximal or nonproximal seg- 
ment]) to determine the importance of new device usage on 
the procedural success for the types of lesions treated with new 
devices. 
Statistical analysis. All data were entered into the MAPS 
Databank at the Data Coordinating Center. Data are ex- 
pressed as mean value _+ 1 SD, unless otherwise noted. 
Intraobserver variability for core angiographic laboratory as- 
sessment of morphologic variables was assessed from observa- 
tions made >6 months apart, using kappa statistics for discrete 
variables and explained variance (r 2) for continuous variables 
on a subset of 30 randomly chosen stenoses (one stenosis per 
patient; 15 patients from each time period). The comparative 
incidences of procedural success, complications and total 
revascularization (the primary end points) were assessed using 
sign-test analysis on a per-patient basis, and procedural success 
was assessed on a per-lesion basis. Multivariate logistic regres- 
sion analysis was performed to assess the influence of lesion 
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Table 1. Comparison ofBaseline Patient and Lesion Characteristics 
Entire 1986-1987 1991 Matched 1986-1987 
Cohort Cohort Cohort 
Patients 
No. of patients 400 200 200 
Age (yr) 58 _+ 11 62 ± 11' 58 + 10 
Current smoking (%) 50.5 50.6 48.5 
Diabetes (%) 18.8 25.0 25.0 
Gender (% male) 71.5 70.5 72.0 
LVEF (%) 58 + I1 56 : 10" 58 ± II 
Previous MI (%) 45.6 52.8 44.2 
Three-vessel disease (c~) 30.0 26.5 30.5 
Unstable angina (%) 47.8 51.5 51.5 
Lesions 
Total no. of lesions 1,235 590 642 
No. of lesions treated 773 406 393 
Angulated ->45 (%) 20.8 16.4 21.1 
Bifurcation (%) 22.8 14.7" 17.6 
Calcified (%) 8.1 13.6~ 9.9 
Chronic total occlusion (%) 4.3 6.2 5.1 
Eccentric (%) 29.0 46.3* 33.1 
High grade (>80%) (%) 24.2 26.9 24.9 
Lesion ->10 mm (%) 11.2 13.8 11.9 
Modified ACC/AHA score 
A 29.2 32.5 32.8 
BI 35.1 33.2 33.1 
B2 24.2 21.7 22.9 
C 11.5 14.5 11.2 
Ostial (%) 3.9 3.0 3.6 
Irregular contour (%) 27.2 16.1 * 21.9 
Restenosis lesion (%) 5.4 4.7 5.1 
Thrombus (%) 4.2 3.8 4.1 
Tortuosi~' (%) 14.1 14.6 14.0 
*p < 0.001 (or p < 0.05 for a primary or secondary end point) versus the entire 1986-1987 cohort, tp < 0.05 versus 
the entire 1986-1987 cohort. Data presented are mean value ± SD, unless otherwise indicated. ACC/AHA - American 
College of Cardiology/American Heart Association; LVEF = left ventricular ejection fraction; MI = myocardial infarction. 
morphology on treatment used and outcome. Analysis of 
covariance was used to examine possible heterogeneity of
treatment effect by hospital site. Kaplan-Meier survival curves 
were generated to describe freedom from long-term events, 
and Cox analyses were performed to assess differences in 
long-term outcome between the study groups. For primary and 
secondary end points, p -< 0.05 was considered significant. For 
other comparisons, to lessen the risk of a type II statistical 
error, p _< 0.001 was regarded as definitely significant and 
0.002 _< p <_ 0.05 as possibly significant. All analyses were 
performed using SYSTAT software (System for Statistics, 
Systat version 5.03 and Survival version 1.0). 
Resu l ts  
Comparison of overall 1986-1987 cohort and 1991 cohort. 
During the period of patient recruitment in early 1991, 1,265 
patients underwent percutaneous revascularization at the five 
centers (the study cohort represents 16% of all treated pa- 
tients). Data are not available as to how many of the 1,265 
patients had previous bypass urgery and hence were excluded 
from recruitment. 
The study cohort of 200 patients consecutively treated in 
1991 were older (p < 0.001) and had a somewhat lower left 
ventricular ejection fraction (p = 0.009) than the 400 patients 
treated earlier (Table 1). There were 590 significant lesions 
(2.95 _+ 1.08/patient) and 406 lesions with attempted treatment 
(68.8% of the significant lesions) in the 1991 cohort, and 1,235 
lesions (3.09 _+ 1.10/patient) and 773 lesions with attempted 
treatment (62.6%) in the 1986-1987 cohort (difference be- 
tween percent of lesions with attempted treatment, p = 0.01). 
There was no difference in overall stenosis complexity (modi- 
fied ACC/AHA score) between the groups. 
Use and results of balloon angioplasty and newer tech- 
niques in the 1991 cohort. Balloon angioplasty was used as 
primary treatment in 335 of the 406 lesions treated (82.5%). 
Success was achieved in 292 lesions (87.2%), and complica- 
tions occurred during treatment of 4 lesions (1.2%). New 
devices were used most commonly in ostial, calcified, lengthy 
or thrombus-containing lesions. Rotablator t eatment (n = 33) 
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Table 2. Comparison of 1986-1987 and 1991 Procedural Outcomes 
(matched analysis) 
1986-1987 1991 p Valuc 
Procedural success (%) 83.5 90.0 0.04 
Complications (%) 8.0 3.5 0.06 
Bypass urgery 5.5 1.0 0.006 
Myocardial infarction 2.0 1.5 NS 
Death 1.0 1.0 NS 
Total revascularization (%) 21.5 35.0 0.003 
was used significantly more often for calcified (p < 0.001) and 
ostial (p = 0.001) lesions and somewhat more often for 
bifurcation (p = 0.03) and high grade lesions (p = 0.05) than 
for treatment of lesions with other morphologies. Success was 
achieved in 32 of (97%) 33 lesions, and complications occurred 
in 1 of (3%) 33. Directional atherectomy (n = 25) was used 
more commonly for irregularly contoured (p = 0.02) or 
proximal esions (p = 0.02). Success was achieved in 22 of 
(88%) 25 of lesions, and complications occurred in 2 of (8%) 
25 of lesions. Stent placement for abrupt closure (n = 6) and 
excimer laser treatment (n = 3) were used less frequently. In 
this group no stent was placed prophylactically in an attempt to 
prevent restenosis. Procedural success continued to be highly 
correlated with modified ACC/AHA lesion classification (11): 
typeA = 127 of (94.8%) 134; type B1 = 125 of (93.3%) 134; tkT)e 
B2 = 63 of (78.8%) 80; and type C = 42 of (72.4%) 58, p < 
0.001. There was no significant heterogenei~ of treatment 
effect by hospital site. 
Comparison of paired 1986-1987 and 1991 patient and 
lesion outcomes. Composite clinical outcome was superior in 
the 1991 group, primarily because of more complete revascu- 
larization (p = 0.003), less frequent need for emergency bypass 
surgery (p = 0.006) and a higher rate of procedural success 
(p = 0.04) (Table 2). Results of the paired lesion analysis are 
shown in Table 3 and demonstrate superior outcome for the 
1991 cohort in terms of procedural success (p = 0.004) and 
final diameter of stenosis (p < 0.001). In the 1991 cohort, 
multivariate logistic regression found lesion failure to be 
associated most closely with long-term total occlusion (success 
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Figure 1. Kaplan-Meier product-limit estimates (--SE) for infarct-free 
survival for the two cohorts. 
0.022) and angle ->45 ° (success 83.6%, p = 0.030). When none 
of these characteristics was present, success was obtained in 
92.6%. When the modified ACC/AHA lesion classification was 
entered first in the stepwise regression, no other variable 
achieved statistical significance as a predictor of success. 
Twelve-month outcome. Clinical follow-up was available in 
394 of (98.5%) 400 of patients. Infarct-free and event-free 
survival is shown in Figures 1 and 2. Event-free survival was 
superior in the 1991 cohort (p = 0.02) largely because of better 
early outcome, but there was no difference in either survival or 
infarct-free survival. Bypass surgery was used in 13.4% versus 
8.1% (p = 0.07) and repeat revascularization bypercutaneous 
intervention alone in 16.2% versus 13.2% (p = NS) of the 
1986-1987 and 1991 cohorts, respectively. 
Reproducibility of assessment of lesion morphology. The 
following kappa values were obtained in the reproducibility 
evaluation: angulation 0.65, bifurcation 0.67, calcification 0.71, 
chronic total occlusion 1.00, irregular contour 0.66, modified 
ACC/AHA classification 0.64, ostial 0.92, tortuosity 0.81 and 
thrombus 0.87 (all p < 0.001). Correlation between readings of 
lesion length (LL) was good (LL 1 = 1.18LL 2 - 0.64 [ram], r2 = 
0.98, p < 0.001). 
Table 3. Comparison of Outcomes for Types of Lesions Treated With New Devices in 1991 
(matched analysis) 
1986-1987 1991 p Value 
No. of patients 98 50 
No. of lesions 130 65 
Age (yr) 60 _+_ 10 61 _+ 12 NS 
Gender (% male) 66.9 63.1 NS 
Angina class 3.0 + 1.2 3.4 = 0.9 0.008 
Pretreatment % stenosis 71 + 15 69 _+ 16 NS 
Posttreatment % stenosis 40 2 19 27 _+ 15 < 0.001 
Procedural success (%) 80.0 92.3 0.004 
Procedural complication (%) ~.2 4.6 NS 
Data presented are mean value _+ SD, unless othem, ise indicated. 
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Figure 2. Kaplan-Mcier p oduct-limit estimates (_+SE) for event-free 
survival (freedom from death, infarction, bypass urgery and repeat 
percutaneous intervention) forthe two cohorts. 
Discuss ion  
Status of percutaneous coronary intervention. In 1994, 
>410,000 coronary angioplasties and directional atherecto- 
mies were performed in the United States (USCI Division of 
C. R. Bard, Billerica, Massachusetts, unpublished ata); yet to 
date, despite several ongoing randomized trials comparing 
coronary angioplasty with other forms of therapy, only a few 
early comparative trial results have been reported (8-10,22). 
These showed modest benefit of coronary angioplasty com- 
pared with medical therapy in patients with single-vessel 
disease and mixed results of coronary angioplasty compared 
with bypass urgery in more extensive disease. 
Advances in percutaneous revascularization since 1986- 
1987. The technique of coronary angioplasty has not remained 
static since 1986. Improvements in guide catheter structure and 
internal dimension have led to improved balloon support and 
coronary visualization. For instance, the internal dimensions of 
8F guide catheters were typically 0.079 in. (0.20 cm) in the 1991 
cohort and 0.072 in. (0.18 cm) in the 1986-1987 cohort studied 
(23). Deflated balloon profile has decreased, leading to an 
expected improved ease of stenosis crossing. In 1991, a 3.0-ram 
over-the-wire balloon typically had a 0.034-in. (0.86 cm) cross- 
ing profile, compared with 0.037- to 0.039-in. (0.094 to 
0.099 cm) in 1986-1987 (23). Improvements in trackability and 
pushability were also made but are more difficult o quantify. A 
wide variety of coronary stents, atherectomy devices and lasers 
have been available since the time of the first MAPS registry. 
Although reports of moderate size, single-device experiences 
have been published (15-17,24-28), the results with an inte- 
grated application of a wide variety of such devices, as is 
currently practiced, are not known. 
1991 results. Balloon angioplasty was used as the only 
technique in 75% of patients in this series from five centers 
with a wide array of technologies for treatment. Rotational 
atherectomy was used in 12% of patients and directional 
atherectomy in another 12%, whereas other devices were used 
infrequently. Advances in balloon technology and availability 
of new devices led to a somewhat higher proportion of lesions 
with attempted treatment (p = 0.01) and to a higher incidence 
of eccentric (p < 0.001) and calcified (p = 0.008) lesions within 
the case mix. Furthermore, after matching for major prognos- 
tic indices, overall clinical outcome was clearly improved in the 
1991 cohort compared with that in the 1986-1987 cohort 
(Table 2, Fig. 2). This occurred because of more frequent total 
revascularization (p = 0.003), less emergency bypass urgery 
(p = 0.006), more frequent procedural success (p = 0.04) and 
improved 12-month event-free survival (p = 0.02). Improve- 
ment in 12-month event-free survival appears to have occurred 
during the index hospital stay, and the later curves are essen- 
tially parallel. 
Clinical implications. If verified by other studies, the 
present results suggest that the indications for percutaneous 
revascularization, relative to medical treatment or bypass 
surgery, should be broadened. Thus, the proscription of new 
device use in studies uch as the Bypass Angioplasty Revascu- 
larization Investigation may represent a very important limita- 
tion to the application of their results to patient care in the 
1990s. 
Study limitations. The results of the present study should 
be interpreted with the recognition of several limitations. First, 
the numbers of patients and lesions studied were relatively 
modest, although not so for this type of analysis requiring 
attention to complex angiographic detail. The results, although 
demonstrating an overall improvement between 1986-1987 
and 1991, will thus require confirmation. Nonetheless, the 
likelihood of finding some of these differences by chance 
alone--especially freedom from emergency bypass surgery 
and achievement of total revascularization--is d minishingly 
small. Second, although the patients of the two time cohorts 
were matched for key prognostic variables and appeared 
similar for other recorded variables, it is possible that they 
differed in other important ways. Third, the reproducibility of 
coronary morphologic analysis is somewhat imprecise, and the 
treated lesions in the two groups may have differed more than 
is suggested in Table 1. Nonetheless, the reproducibility of 
results from this core angiographic laboratory are as good as or 
better than those from other, albeit limited, reports (29). 
Fourth, it is not possible to ascertain exactly how much of the 
improvement in procedural outcome in 1991 was due to the 
availability of new techniques and how much was due to 
advances in old ones (coronary angioplasty), although both 
factors appear to have played a role. The frequency of new 
device usage during this study is similar to contemporary use in 
the United States now that these devices are widely available 
(30). Finally, the procedural success rates in the present study 
may appear to be low but in fact are commensurate with those 
from other current studies in which objective measures of 
stenosis dimension were used (31). 
Conclusions. Procedural results of percutaneous coronary 
revascularization at high volume interventional centers with 
access to techniques in addition to coronary angioplasty, as 
well as extensive experience with coronary angioplasty, 
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appeared to have improved considerably between 1986- 
1987 and 1991. This has important implications for patient 
care and for the interpretation of randomized trials enroll- 
ing patients in the late 1980s and intending to define the 
proper role of percutaneous revascularization relative to 
other forms of therapy. 
We thank Patti Durnwald for expert secretarial ssistance. 
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Participating Institutions and Personnel for the 
Multivessel Angioplasty Prognosis Study 
(MAPS) Group 
Medical College of Virginia, Richmond, Virginia: Michael J. Cowley, MD 
(Principal Investigator); Germano DiSciascio, MD, George W. Vetrovec, MD, 
Kim M. Kelley, RN (Coinvestigators). Saint Louis University, Saint Louis, 
Missouri: Frank Aguirre, MD (Principal Investigator); Ubeydullafi Deligonul, 
MD, Morton J. Kern, MD, Kathy Galan, RN, Sue Taussig, RN (Coim'estigators); 
Michel Vandormael, MD (former Coinvestigator). University of Alabama, Bir- 
mingham, Alabama: Larry Dean, MD (Principal Investigator); Gary Roubin, MB, 
PhD, Joan Anderson, RN (Coinvestigators); Thomas Bulle, MD ([ormer Coin- 
vestigator). University of Michigan, Ann Arbor, Michigan: David W.M. Muller, 
MBBS (Coinvestigator); William W. O'Neill, MD, Jeffrey J. Popma, MD ((ormer 
Coinvestigators). Cleveland Clinic Foundation, Cleveland, Ohio: Stephen G. 
Ellis, MD (Principal Investigator); Patrick L. Whitlow, MD, Irving Franco, MD, 
Russ Raymond, DO, Eric J. Topoi, MD, Kelly Brezina, RN, Sue DeLuca, RN, 
Colleen Rouse, RN (Coinvestigators); Jay Hollman, MD (former Coinvestigator). 
Angiographic Core Laboratory: Stephen G. Ellis, MD (Principal Investigator); 
Darrell DeBowey, MS (Coinvesttg, ator); Thomas M. Bulle, MD (former Coinves- 
tigator). Data Coordinating Center: Stephen G. Ellis, MD (Principal Investigator); 
M. Anthony Schork, PhD, Robert Bagen, PhD (Coinvestigators). 
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